Effective strategies against COVID-19 and the importance of infection sequelae - Global Health Research and Policy
Covid19-Sources
Raffy Flynn on Twitter
Autopsy-based histopathological characterization of myocarditis after anti-SARS-CoV-2-vaccination
Acute and postacute sequelae associated with SARS-CoV-2 reinfection
Cardiovascular Disease and COVID-19: Insight From Cases With Heart Failure
Beim Screening auch falsch-positive Tests in Betracht ziehen
Dr Elisa Perego on Twitter
Bert Weingarten on Twitter
Cutting Edge: Circulating Exosomes with COVID Spike Protein Are Induced by BNT162b2 (Pfizer–BioNTech) Vaccination prior to Development of Antibodies: A Novel Mechanism for Immune Activation by mRNA Vaccines
Cases, Data, and Surveillance
A call for immediate action to increase COVID-19 vaccination uptake to prepare for the third pandemic winter
Persistent post–COVID-19 smell loss is associated with immune cell infiltration and altered gene expression in olfactory epithelium
Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster | NEJM
‘It Doesn’t Hurt at All’: In China’s New Covid Strategy, Vaccines Matter
Todesursachenstatistik 2021: 7 % aller Todesfälle gehen direkt auf COVID-19 zurück
SARS-CoV-2 mitochondriopathy in COVID-19 pneumonia exacerbates hypoxemia
The durability of natural infection and vaccine-induced immunity against future infection by SARS-CoV-2
Peak antibody levels elicited by messenger RNA (mRNA) vaccines mRNA-1273 and BNT1262b2 exceeded that of natural infection and are expected to typically yield more durable protection against breakthrough infections (median 29.6 mo; 5 to 95% quantiles 10.9 mo to 7.9 y) than natural infection (median 21.5 mo; 5 to 95% quantiles 3.5 mo to 7.1 y). Relative to mRNA-1273 and BNT1262b2, viral vector vaccines ChAdOx1 and Ad26.COV2.S exhibit similar peak anti-S IgG antibody responses to that from natural infection and are projected to yield lower, shorter-term protection against breakthrough infection (median 22.4 mo and 5 to 95% quantiles 4.3 mo to 7.2 y; and median 20.5 mo and 5 to 95% quantiles 2.6 mo to 7.0 y; respectively).
The WHO estimates of excess mortality associated with the COVID-19 pandemic
Evaluating vaccine allocation strategies using simulation-assisted...
SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination
Pediatric health system impact of an early respiratory viral season in Eastern Ontario, Canada: A descriptive analysis
COVID spreading faster than ever in China. 800 million could be infected this winter
COVID-19 inhibits spermatogenesis in the testes by inducing cellular senescence
Mucosal Immunity After Novel COVID-19 Infection – Virus-Induced Immunosuppression: Preliminary Study
Vaccine-induced systemic and mucosal T cell immunity to SARS-CoV-2 viral variants
Clinical management of COVID-19: Living guideline, 15 September 2022
Severe COVID-19 is associated with molecular signatures of aging in the human brain
Molecular states during acute COVID-19 reveal distinct etiologies of long-term sequelae - Nature Medicine
What is life expectancy? And, even more important, what it isn’t | R-bloggers